BIOMAT Database Logo BIOMAT Database Logo

Phase I trial of caracemide using bolus and infusion schedules. 1987

M N Raber, and F Adams, and J Kavanagh, and S Legha, and I Dimery, and I Krakoff

We conducted a phase I trial of caracemide, a new chemotherapeutic agent, which is active in the MX1 (mammary) and CX1 (colon) human tumor xenografts. Using a 5-day bolus schedule, dose-limiting toxicity consisting of burning perioral pain associated with flushing, nasal stuffiness, and excess lacrimation was seen at 650 mg/m2/day. Using a 5-day continuous-infusion schedule, dose-limiting toxicity in the form of changes in affect, lethargy, disorientation, and cognitive dysfunction with electroencephalogram abnormalities was noted at 800 mg/m2/day. The recommended phase II dose levels are 525 mg/m2/day using the 5-day bolus schedule and 650 mg/m2/day using the continuous-infusion schedule. Because of venous pain at the site of infusion, the drug must be delivered via central venous access. The pathophysiology of both the peripheral and central side effects of caracemide may be related to increased cholinergic activity.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002493 Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord. CNS Disease,Central Nervous System Disease,Central Nervous System Disorder,CNS Diseases,Central Nervous System Disorders
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M N Raber, and F Adams, and J Kavanagh, and S Legha, and I Dimery, and I Krakoff
One-hour paclitaxel infusion schedules: a phase I/II comparative trial.
June 1995, Seminars in oncology,
M N Raber, and F Adams, and J Kavanagh, and S Legha, and I Dimery, and I Krakoff
Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules.
October 1994, Seminars in oncology,
M N Raber, and F Adams, and J Kavanagh, and S Legha, and I Dimery, and I Krakoff
Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion.
December 1987, Investigational new drugs,
M N Raber, and F Adams, and J Kavanagh, and S Legha, and I Dimery, and I Krakoff
Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
January 1995, The cancer journal from Scientific American,
M N Raber, and F Adams, and J Kavanagh, and S Legha, and I Dimery, and I Krakoff
Intravenous vincristine infusion: phase I trial.
December 1981, Cancer,
M N Raber, and F Adams, and J Kavanagh, and S Legha, and I Dimery, and I Krakoff
Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
August 1994, Cancer,
M N Raber, and F Adams, and J Kavanagh, and S Legha, and I Dimery, and I Krakoff
Phase I trial of cremophor EL with bolus doxorubicin.
October 1998, Clinical cancer research : an official journal of the American Association for Cancer Research,
M N Raber, and F Adams, and J Kavanagh, and S Legha, and I Dimery, and I Krakoff
Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
February 1992, Blood,
M N Raber, and F Adams, and J Kavanagh, and S Legha, and I Dimery, and I Krakoff
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
February 1982, Journal of the National Cancer Institute,
M N Raber, and F Adams, and J Kavanagh, and S Legha, and I Dimery, and I Krakoff
Phase I study of oral doxifluridine using two schedules.
May 1989, European journal of cancer & clinical oncology,
Copied contents to your clipboard!